Biography and Research Information
OverviewAI-generated summary
Orwa Aboud, an Assistant Professor at the University of Arkansas for Medical Sciences, investigates the molecular mechanisms and potential therapeutic targets for brain tumors, particularly gliomas and glioblastomas. His research employs advanced techniques, including metabolomics and machine learning, to characterize these complex diseases. Recent work has focused on identifying lipidomic signatures and analyzing mitochondrial ultrastructure in different glioma subtypes, aiming to uncover novel diagnostic and prognostic markers. Aboud also explores the efficacy of targeted therapies, such as Epidermal Growth Factor Receptor inhibitors and BRAF inhibitors, in treating specific mutations found in brain tumors and craniopharyngiomas. His scholarship includes 120 publications and 539 citations, with an h-index of 12. He collaborates with researchers at his institution, including Meenakshisundaram Balasubramaniam, W. Sue T. Griffin, Srinivas Ayyadevara, and Narasimhappagari Jagadeesh.
Metrics
- h-index: 12
- Publications: 120
- Citations: 562
Selected Publications
-
Abstract LB131: The role of the proinflammatory cytokine IL-1β and its signaling cascade in glioblastoma pathogenesis and the therapeutic effect of IL-1RA and Tolcapone as anticancer agents (2025)
Collaboration Network
Top Collaborators
- Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation
- Comparative survey of mitochondrial ultrastructure in <i>IDH1</i>-mutant astrocytoma and <i>IDH1</i>-wildtype glioblastoma (GBM)
- Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
- Astrocytoma and glioblastoma IDH1-wildtype cells colonize tumor vessels and deploy vascular mimicry
- H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review
Showing 5 of 13 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
- INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 12 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
- Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 11 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch
- INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 11 shared publications
- Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation
- A pilot study on metabolomic characterization of human glioblastomas and patient plasma
- Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment
- Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment
- Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Showing 5 of 11 shared publications
- Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation
- A pilot study on metabolomic characterization of human glioblastomas and patient plasma
- Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment
- Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment
- Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Showing 5 of 11 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 10 shared publications
- Excessive lipid production shapes glioma tumor microenvironment
- Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment
- Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment
- Metabolic Risk Factors and Survival in Patients with Glioblastoma
- Excessive Lipid Production Shapes Glioma Tumor Microenvironment
Showing 5 of 10 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics